Overview

Location [1]
1q25.2
Protein [2]
Tyrosine-protein kinase ABL2
Synonyms [1]
ARG, ABLL

ABL proto-oncogene 2, non-receptor tyrosine kinase (ABL2) is a gene that encodes a protein non-receptor tyrosine kinase. The protein functions in cytoskeletal rearrangements. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift insertions and deletions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.

ABL2 is altered in 0.26% of all cancers with breast invasive ductal carcinoma having the greatest prevalence of alterations [3].

ABL2 GENIE Cases - Top Diseases

The most common alteration in ABL2 is ABL2 Amplification (0.03%) [3].

ABL2 GENIE Cases - Top Alterations

Significance of ABL2 in Diseases

Acute Lymphoblastic Leukemia +

B-Cell Acute Lymphoblastic Leukemia +

Acute Myeloid Leukemia +

Myelodysplastic Syndromes +

Breast Carcinoma +

Malignant Solid Tumor +

Anaplastic Astrocytoma +

Bladder Carcinoma +

Chronic Myeloid Leukemia +

Chronic Myelomonocytic Leukemia +

Colorectal Carcinoma +

Glioblastoma +

Head And Neck Carcinoma +

Lymphoma +

Melanoma +

Non-Small Cell Lung Carcinoma +

Ovarian Carcinoma +

Pancreatic Carcinoma +

Sarcoma +

Secondary Acute Myeloid Leukemia +

Therapy-Related Acute Myeloid Leukemia +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.